Efgartigimod, a treatment approved for certain autoimmune diseases, was linked to maintained clinical responses and low disease activity scores for up to 72 weeks in people with Sjögren’s disease, according to data from a small Phase 2 clinical trial and its open-label extension study. Participants who showed a clinical…
News
People with primary Sjögren’s disease and their close family members have a higher risk of developing cancer than the general population, according to a study out of Turkey. While Sjögren’s has been associated with a higher risk of cancer, the potential risk among family members is a new…
Through detailed computer-based analyses of publicly available genetic data sets, a team of scientists in China has identified three genes that are overactive in people with Sjögren’s disease, according to a study. The scientists are hopeful that, with further validation, these genes may be used as markers to aid…
A global clinical trial testing Immunovant’s injection therapy IMVT-1402 against a placebo in adults with Sjögren’s disease is still recruiting participants, and remains on track to provide initial data in 2028. That’s according to a press release from the company, a Roivant subsidiary, announcing Immunovant’s latest…
Dianthus Therapeutics has selected Sjögren’s disease as one of the first three priority indications for the clinical development of DNTH212, its experimental therapy for autoimmune conditions. The treatment is currently being tested in healthy adult volunteers in a China-based Phase 1 clinical trial (NCT07323173), with top-line data…
Efgartigimod, a therapy approved for certain autoimmune diseases, led to higher response rates and greater reductions in certain immune markers than a placebo in adults with Sjögren’s disease, according to final data from a small proof-of-concept clinical trial. Because the Phase 2 study, called RHO (NCT05817669), was not…
Women and men with Sjögren’s disease may experience the condition differently, particularly in the type and severity of symptoms and the organs affected, a study in the Netherlands suggests. While women were more likely to report dry eyes and dry mouth — the hallmark Sjögren’s symptoms — and…
People with Sjögren’s disease don’t only have to deal with eye and mouth dryness, but also a wide range of other symptoms that can include fatigue, pain, brain fog, and difficulty sleeping, according to a U.S. survey conducted by the Sjögren’s Foundation. In fact, results from the…
Blood levels of two self-targeting antibodies commonly elevated in people with Sjögren’s disease may define distinct patient groups with different levels of disease severity and organ involvement, a single-center study in China shows. For example, testing positive for anti-Ro52 antibodies alone was associated with lung disease, while testing positive…
The first patient has been dosed in a newly launched global clinical trial evaluating the safety and effectiveness of telitacicept, given as subcutaneous, or under-the-skin, injections, in adults with primary Sjögren’s disease. The Phase 3 study, dubbed UPSTREAM SjD (NCT07404865), will test the therapy, in an estimated 250…
Recent Posts
- FDA OKs drug’s new oral formulation for treating Sjögren’s dry mouth
- New blood markers may help diagnose Sjögren’s when antibodies are absent
- Florida father to paddle 540 miles for Sjögren’s disease research
- Argenx stops Sjögren’s drug trial after analysis shows ‘futility’
- Add-on cell therapy may ease Sjögren’s symptoms, boost saliva
- Experimental therapy rapidly lowers disease activity in Sjögren’s trial
- Study links salivary gland swelling to distinct Sjögren’s profile
- Four-gene signature may help identify Sjögren’s disease, study finds
- Global trial testing oral Sjögren’s treatment seeking over 300 patients
- Lung decline stays steady despite rise in Sjögren’s ILD treatment